Navitoclax has been applied to boost the treatment and basic science of chronic lymphoid leukemia, hematological malignancies, non-Hodgkin's lymphoma, solid tumors, and EGFR activating mutation. The gene discussed is EGFR; the disease is hematologic disorder.